Norwegian version of this page

Kidney Transplantation

The group initiates and participates in studies focusing on renal transplant patients. The research is clinically oriented towards these patients.

About the group

The research group carries out epidemiological and clinical outcome studies in kidney transplantation, pancreas transplantation and islet transplantation.

Data from the Norwegian Renal Registry (which is updated yearly) together with data from a local biobank are generated, together with RCTs and observational studies.

The studies focus on immunotherapy, pharmacokinetics, pharmacotherapeutic modelling and metabolism, in particular metabolism in post-transplant diabetes (PTDM).

Clinical studies are oriented on outcomes and complications after kidney and pancreas transplantation including epidemiological studies, RCT’s and explanatory studies of mechanisms and pathogenesis.

The studies include immunotherapy and pharmacokinetics and pharmacotherapeutic modelling. For epidemiological studies local biobank and follow up via Norwegian Renal Registry are essential.


  • Post-transplant diabetes
  • Kidney rejection and immunity
  • Osteoporosis after transplantation
  • Visceral fat and inflammation
  • Individualization of immunosuppression, also with home based blood sampling (MitraTip®)
  • Biomarkers of outcomes after transplantation
  • Adherence of immunosuppressive treatment
  • Pregnancy and transplantation
  • Measured GFR by iohexol plasma clearance
  • Estimated glomerular filtration rate
  • Evaluation and follow-up of kidney donors 



  • Section of Endocrinology
  • Section of Transplant surgery
  • Department of Pathology
  • Department of Immunology
  • Department of Pediatrics


  • University of Oslo, AHUS - Renal research Group
  • University of Tromsø- Renal research Group
  • University of Bergen- Department of nephrology
  • University of Stavanger, Department of nephrology
  • School of Pharmacy, UiO
  • Department of Nutrition, UiO


  • Laboratory for Applied Pharmacokinetics and Bioinformatics, University of Southern California
  • Professor Esteban Porini, La Laguna University, Tenerife, Spain
  • Professor Manfred Hecking, Medical Universtiy of Vienna, Austria
  • CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France
  • Andreas Paasch, Caltec, Basel
  • Professor Filip Knop, Center for Diabetes Research, Gentofte Hospital, Copenhagen
  • Professor Bo Feldt-Rasmussen, Department of Nephrology, Rigshospitalet, Copenhagen


  1. Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Åsberg A, Jensen T. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients with Post-Transplant Diabetes Mellitus. Diabetes Care 2019; 42(6): 1067-1074.
  2. Gustavsen MT, Midtvedt K, Lønning K, Jacobsen T, Reisæter AV, De Geest S, Andersen MH, Hartmann A, Åsberg A. Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation. Transplant Int 2019; 32(6): 614-625.
  3. Pihlstrøm HK, Mjøen G, Mucha S, Franke A, Jardine A, Fellström B, Dahle DO, Holdaas H, Melum E. Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients. Am J Transplant. 2019; 19(5): 1444-1451.
  4. Haugen AJ, Langberg NE, Dahle DO, Pihlstrøm H, Birkeland KI, Reisaeter A, Midtvedt K, Hartmann A, Holdaas H, Mjøen G. Long-term risk for kidney donors with hypertension at donation - a retrospective cohort study. Transpl Int. 2019; 32(9): 960-964. 
Published Aug. 14, 2018 10:36 AM - Last modified May 8, 2020 11:18 AM


Group leader


Detailed list of participants